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toxicity ≥G2 was observed in 111 (42.7%) pts, 65 (25%) pts presented
with infections and 44 (17%) pts with febrile neutropenia.
Bleomycin lung-toxicity (BLT) was documented in 25 (18%) pts:
6 (4 %) pts had mild toxicity (radiologic changes only), 12 (9%) pts had
severe toxicity (leading to hospitalization), in 7 (5%) pts severity was
unknown.
In 58 (24%) pts treatment was discontinued prematurely due to toxic-
ity. 171 (68.7%) pts achieved complete remission, 30 (12%) partial
response. 58 (23%) pts relapsed/progressed after first line treatment.
25 (23%) pts died of HL and 15 (14%) of treatment toxicity. With a
median follow-up of 4.1 years (range: 0.05 - 17.95) for the whole
study population, progression-free survival (PFS) at 2 and 5 years was
81% and 72% respectively, cause-specific survival (CSS) at 2 and
5 years was 85% and 78%, respectively. CSS for pts 71-80 years vs
60-70 years; HR = 3.25, p<0.001 and > 80 years vs 60-70 years; HR
3.84, p = 0.001.
Conclusion: Cause-specific survival of unselected, elderly HL pts >
71 years decreased significantly in comparison to those 60 to 70 years.
Toxicities appeared to be relevant, in particular infections and BLT.
Bleomycin needs to be used with extreme caution in this particular
group of patients. New treatment strategies with a low toxicity profile
are clearly needed, in particular for frail pts and pts older than
70 years.
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Introduction: Soluble (s)CD30 and thymus and activation-regulated
chemokine (TARC) are established prognostic biomarkers in Hodgkin
lymphoma (HL): higher baseline serum levels are associated with
poorer survival outcomes. Elevated sCD30 and TARC levels are also
associated with established poor prognostic factors in HL, e.g. Stage
IV disease, higher International Prognostic Score (IPS), and extranodal
involvement (ENI). The phase 3 ECHELON-1 study compared front-
line brentuximab vedotin (a CD30-directed antibody-drug conjugate)
plus doxorubicin, vinblastine, and dacarbazine (A+AVD) vs ABVD in
patients (pts) with advanced classical HL (cHL). A+AVD demonstrated
superior modified progression-free survival (modified PFS) vs ABVD
(HR = 0.77 [95% CI 0.60–0.98]; p = 0.035; 2-yr mPFS 82.1% vs
77.2%. An exploratory ad-hoc biomarker analysis evaluated mPFS
according to baseline sCD30 and TARC levels.
Methods: Serum samples were collected from 1334 pts with Stage III
(36%) or IV (64%) cHL during the screening period and analyzed using
validated assays for sCD30 (Covance Labs) and TARC (ICON Labs).
mPFS (defined as time to progression, death, or evidence of
noncomplete response followed by subsequent anticancer therapy)
per independent review facility (IRF) was analyzed according to base-
line sCD30 and TARC levels; the association of biomarker levels with
treatment outcomes along with other potential predictive factors was
explored in a multivariate Cox model.
Results: For the ad-hoc sCD30 analysis, pts were dichotomized
around the median sCD30 baseline level (207.9 ng/mL). Pts in the A
+AVD arm performed similarly regardless of baseline sCD30 level,
with a 2-yr mPFS of 80.7% (sCD30 >median) and 82.7% (sCD30
≤median). However, a decrease in effectiveness of ABVD was
observed in pts with sCD30 >median with a 2-yr mPFS of 68.9%
[sCD30 >median] and 85.7% [sCD30 ≤median]). A mPFS benefit in
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favor of A+AVD vs ABVD was observed in pts with sCD30 >median
(HR (95% CI) = 0.600 (0.428-0.841)) . Multivariate Cox analysis with
the interaction between treatment group and sCD30 level showed an
increased risk of experiencing an mPFS event with ABVD and sCD30
>median (interaction p = 0.025) when adjusted by other prognostic
factors (Ann Arbor stage, IPS and ENI). Similar trends were observed
with the exploratory ad-hoc TARC analysis. No new safety signals
were reported in subgroups with elevated sCD30 or TARC levels.
Conclusions: Preliminary adhoc analysis indicates that ABVD treated
patients do not perform as well with elevated baseline sCD30 and
TARC levels. A+AVD treated patients perform well regardless of levels
of these poor prognostic markers. Prospective studies need to be con-
ducted in order to further validate these findings. If validated, these
biomarkers may help identify patient populations that could benefit
from more effectively targeted therapy.
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